Onderneming Novo Nordisk A/S Xetra

DK0060102614

Farmaceutische producten

Vakgebied

Verkoop per activiteit

Verkoop per regio

Managers

Besturend

Aandelenklasse

Aandeelhouders

Participaties

Bedrijfsgegevens

Bedrijven van de groep

Sector

Verkoop per activiteit

Verkoop per regio

Sector Farmaceutische producten - Andere

Inactief instrument

slotkoers Xetra Andere beurzen
- ^EUR	-

31/05	Zealand Pharma krijgt steun van EU Panel voor behandeling van ernstige hypoglykemie	MT
30/05	Deense overheid voert strengere subsidieregels in voor diabetesmedicijnen	MT

Novo Nordisk A/S is gespecialiseerd in het ontwerpen, vervaardigen en op de markt brengen van farmaceutische producten. De netto-omzet is als volgt over de productfamilie verdeeld:
- producten voor de behandeling van diabetes en obesitas (92,6%);
- producten voor de behandeling van zeldzame ziekten (7,4%): bedoeld voor de behandeling van hemofilie, bloedziekten, hormonale stoornissen, enz.
De netto-omzet is geografisch als volgt verdeeld: Europa/Midden-Oosten/Afrika (21,9%), de Verenigde Staten (54,9%), Noord-Amerika (3,9%), China (7,2%) en overige (12,1%).

DKK in miljoen	2022	Gewicht	2023	Gewicht	Delta
Diabetes and Obesity Care 92,6 %	156 412	88,4 %	215 098	92,6 %	+37,52%
Rare Disease 7,4 %	20 542	11,6 %	17 163	7,4 %	-16,45%

DKK in miljoen	2022	Gewicht	2023	Gewicht	Delta
United States 54,9 %	84 656	47,8 %	127 534	54,9 %	+50,65%
EMEA 21,9 %	44 236	25,0 %	50 867	21,9 %	+14,99%
Rest of the World 12,1 %	25 402	14,4 %	28 078	12,1 %	+10,53%
China 7,2 %	16 209	9,2 %	16 687	7,2 %	+2,95%
Canada 3,9 %	6 451	3,6 %	9 095	3,9 %	+40,99%

Managers	Titel	Leeftijd	Van
Lars Fruergaard Jorgensen CEO	Chief Executive Officer	58	01-01-91
Karsten Munk Knudsen DFI	Director of Finance/CFO	53	01-01-99
Stephen Gough CTO	Chief Tech/Sci/R&D Officer	-	01-10-15
Marcus Schindler CTO	Chief Tech/Sci/R&D Officer	57	01-01-18
Maziar Mike Doustdar COO	Chief Operating Officer	54	01-01-92
Henrik Ehlers Wulff CTO	Chief Tech/Sci/R&D Officer	54	01-01-99
Daniel Bohsen IRC	Investor Relations Contact	-	01-03-20
Tania Sabroe HRO	Human Resources Officer	47	01-01-07
Irina Ivanischeva LAW	General Counsel	-	-
Sergey Manelis PRN	Corporate Officer/Principal	-	13-07-20

Besturend	Titel	Leeftijd	Van
Sylvie Grégoire BRD	Director/Board Member	62	19-03-15
Helge Lund CHM	Chairman	61	23-03-17
Martin MacKay BRD	Director/Board Member	68	01-03-18
Laurence Debroux BRD	Director/Board Member	54	21-03-19
Kasim Kutay BRD	Director/Board Member	59	23-03-17
Andreas Fibig BRD	Director/Board Member	62	01-03-18
Henrik Poulsen BRD	Director/Board Member	57	25-03-21
Liselotte Hyveled BRD	Director/Board Member	58	01-01-92
Mette Bøjer Jensen BRD	Director/Board Member	49	22-03-18
Thomas Rantzau BRD	Director/Board Member	52	22-03-18

	Stemming	Aantal	Vrij verhandelbaar	Bedrijfseigen aandelen	Drijvend Totaal
Aandeel A	10	1 075 000 000	0	0	70,17 %
Aandeel B	1	3 390 128 000	3 133 044 416 ( 92,42 %)	51 700 000 ( 1,525 %)

Naam	Aandelen	%	Totale waarde
ATP Fondsmaeglerselskab A/S 8,814 %	298 789 780	8,814 %	38 663 M €
Novo Holdings A/S (Investment Company) 5,610 %	190 183 000	5,610 %	24 609 M €
NOVO NORDISK A/S 1,444 %	48 963 707	1,444 %	6 336 M €
Pensionskassernes Administration A/S 0,7442 %	25 229 760	0,7442 %	3 265 M €
PFA Kapitalforvaltning Fondsmæglerselskab A/S 0,6990 %	23 696 970	0,6990 %	3 066 M €
MP Investment Management A/S 0,5922 %	20 075 914	0,5922 %	2 598 M €
Capital International KK 0,2986 %	10 123 000	0,2986 %	1 310 M €
Universal-Investment-Gesellschaft mbH (Invt Mgmt) 0,2336 %	7 919 037	0,2336 %	1 025 M €
State Street Global Advisors Ltd. 0,2108 %	7 145 424	0,2108 %	925 M €
Nordea Investment Management AB 0,1948 %	6 605 247	0,1948 %	855 M €

Naam	Aandelen	%	Totale waarde
Novo Holdings A/S (Investment Company) 100,00 %	1 074 872 000	100,00 %	139 md. €
ANIMA Sgr SpA 0,0197 %	211 527	0,0197 %	27 M €
Fineco Asset Management DAC 0,009413 %	101 181	0,009413 %	13 M €
NS Partners SA 0,006408 %	68 876	0,006408 %	9 M €
Kieger AG 0,002940 %	31 596	0,002940 %	4 M €
Mercer Global Investments Europe Ltd. 0,002487 %	26 732	0,002487 %	3 M €
OLZ AG 0,001913 %	20 557	0,001913 %	3 M €
Union Bancaire Privée, UBP SA 0,001241 %	13 340	0,001241 %	2 M €
Swissinvest Institut für Angewandte Finanzmarktanalysen GmbH 0,000698 %	7 500	0,000698 %	970 489 €
DJE Kapital AG 0,000616 %	6 616	0,000616 %	856 101 €

Naam	Aandelen	%	Totale waarde
Jennison Associates LLC 0,6219 %	21 084 614	0,6219 %	2 652 M €
Fidelity Management & Research Co. LLC 0,5193 %	17 604 322	0,5193 %	2 214 M €
Merrill Lynch International 0,4150 %	14 068 584	0,4150 %	1 770 M €
Fisher Asset Management LLC 0,4048 %	13 724 718	0,4048 %	1 726 M €
Eaton Vance Management 0,3543 %	12 011 853	0,3543 %	1 511 M €
Fayez Sarofim & Co. 0,3485 %	11 815 837	0,3485 %	1 486 M €
Renaissance Technologies LLC 0,3182 %	10 786 074	0,3182 %	1 357 M €
Royal Trust Corp. of Canada 0,2860 %	9 695 203	0,2860 %	1 220 M €
Loomis, Sayles & Co. LP 0,2611 %	8 852 532	0,2611 %	1 114 M €
Folketrygdfondet 0,2583 %	8 756 034	0,2583 %	1 101 M €

Naam	Aandelen	%	Totale waarde
NOVO NORDISK A/S 1.44%	48 963 707	1.44%	6 335 831 220 $
NNIT A/S 17.50%	4 375 000	17.50%	67 111 319 $
INNATE PHARMA 12.14%	9 817 546	12.14%	23 146 828 $

Novo Nordisk A/S

Novo Allé 1

2880, Bagsværd

+45 44 44 88 88

http://www.novonordisk.com

Naam	Categorie en sector
Novo Nordisk India Pvt Ltd. Novo Nordisk India Pvt Ltd. Medical/Nursing ServicesHealth Services Part of Novo Nordisk A/S, Novo Nordisk India Pvt Ltd. is a leading healthcare company founded in 1923 and headquartered in Denmark. The company is based in Bengaluru, India. Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases.	Medical/Nursing Services
Velfærdsfonden for Novo Nordisk A/S	Investment Trusts/Mutual Funds
NNE A/S NNE A/S Engineering & ConstructionIndustrial Services Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The company is based in Soborg, Denmark.	Engineering & Construction
World Diabetes Foundation	Investment Trusts/Mutual Funds
Novo Nordisk Health Care AG Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Novo Nordisk Health Care AG engages in the production and distribution of chemical and pharmaceutical products as well as articles for diagnostic and therapeutic applications. It also specializes in the research in and development of products, therapeutic methods, and display techniques primarily used in the chemical, pharmaceutical, and diagnostic fields. The company was founded on August 10, 2000 and is headquartered in Zurich, Switzerland.	Pharmaceuticals: Major
Novo Nordisk Finance (Netherlands) BV	Finance/Rental/Leasing
Novo Nordisk Region Europe A/S Novo Nordisk Region Europe A/S Financial ConglomeratesFinance Novo Nordisk Region Europe A/S holds ownership interests in other companies to undertake investment and financing activities. It offers service on an operational basis, including the placement of capital in companies and real estate. The company was founded September 14, 2001 and is headquartered in Bagsvaerd, Denmark.	Financial Conglomerates

Gezondheidszorg

Farmaceutisch en medisch onderzoek

Farmaceutische producten

Farmaceutische producten

Farmaceutische producten - Andere

	Vaira. 1 jan.	Kapi.
ELI LILLY AND COMPANY	+40,73%	739 mld.
JOHNSON & JOHNSON	-6,30%	353 mld.
MERCK & CO., INC.	+15,15%	318 mld.
ABBVIE INC.	+4,05%	285 mld.
ASTRAZENECA PLC	+15,00%	240 mld.
NOVARTIS AG	+9,78%	210 mld.
ROCHE HOLDING AG	-5,52%	206 mld.
AMGEN INC.	+6,17%	164 mld.
PFIZER, INC.	-0,45%	162 mld.

Farmaceutische producten - Andere